Depreciation of Entrada Therapeutics, Inc. from 30 Sep 2020 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Entrada Therapeutics, Inc. quarterly and annual Depreciation in USD history and change rate from 30 Sep 2020 to 31 Dec 2025.
  • Entrada Therapeutics, Inc. Depreciation for the quarter ending 31 Dec 2025 was $850,000, a 18% decline year-over-year.
  • Entrada Therapeutics, Inc. Depreciation for the twelve months ending 31 Dec 2025 was $4,096,000, a 8.6% increase year-over-year.
  • Entrada Therapeutics, Inc. annual Depreciation for 2025 was $4,096,000, a 8.6% increase from 2024.
  • Entrada Therapeutics, Inc. annual Depreciation for 2024 was $3,773,000, a 33% increase from 2023.
  • Entrada Therapeutics, Inc. annual Depreciation for 2023 was $2,841,000, a 50% increase from 2022.
Source SEC data
View on sec.gov
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Change (%)
Depreciation, Annual (USD)
Depreciation, YoY Annual Change (%)

Entrada Therapeutics, Inc. Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $4,096,000 $850,000 -$189,000 -18% 01 Oct 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
Q3 2025 $4,285,000 $1,200,000 +$300,000 +33% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $3,985,000 $1,100,000 +$200,000 +22% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $3,785,000 $946,000 +$12,000 +1.3% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $3,773,000 $1,039,000 +$239,000 +30% 01 Oct 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
Q3 2024 $3,534,000 $900,000 +$100,000 +12% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $3,434,000 $900,000 +$200,000 +29% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $3,234,000 $934,000 +$393,000 +73% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $2,841,000 $800,000 +$295,000 +58% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $2,546,000 $800,000 +$300,000 +60% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $2,246,000 $700,000 +$200,000 +40% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $2,046,000 $541,000 +$151,000 +39% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $1,895,000 $505,000 +$187,000 +59% 01 Oct 2022 31 Dec 2022 10-K 13 Mar 2024 2023 FY
Q3 2022 $1,708,000 $500,000 +$200,000 +67% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $1,508,000 $500,000 +$200,000 +67% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $1,308,000 $390,000 +$191,000 +96% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q4 2021 $1,117,000 $318,000 01 Oct 2021 31 Dec 2021 10-K 06 Mar 2023 2022 FY
Q3 2021 $300,000 +$200,000 +200% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 $300,000 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $199,000 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q3 2020 $100,000 01 Jul 2020 30 Sep 2020 10-Q 09 Dec 2021 2021 Q3

Entrada Therapeutics, Inc. Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $4,096,000 +$323,000 +8.6% 01 Jan 2025 31 Dec 2025 10-K 26 Feb 2026 2025 FY
2024 $3,773,000 +$932,000 +33% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2026 2025 FY
2023 $2,841,000 +$946,000 +50% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $1,895,000 +$778,000 +70% 01 Jan 2022 31 Dec 2022 10-K 13 Mar 2024 2023 FY
2021 $1,117,000 +$791,000 +243% 01 Jan 2021 31 Dec 2021 10-K 06 Mar 2023 2022 FY
2020 $326,000 01 Jan 2020 31 Dec 2020 10-K 15 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.